Stability-indicating RP-LC method for quantification of fusidic acid in cream by Curbete, Mariane Machado & Salgado, Hérida Regina Nunes
*Correspondence: M. M. Curbete. School of Pharmaceutical Sciences, UNESP. 
Universidade Estadual Paulista. Rodovia Araraquara- Jaú, km 1, 14800-901 – 
Araraquara - São Paulo, Brazil. E-mail: mari_curbete@hotmail.com
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 52, n. 3, jul./sep., 2016
http://dx.doi.org/10.1590/S1984-82502016000300011
Stability-indicating RP-LC method for quantification of fusidic acid 
in cream
Mariane Machado Curbete*, Hérida Regina Nunes Salgado
Department of Pharmaceuticals, School of Pharmaceutical Sciences, UNESP - Univ Estadual Paulista, Campus de 
Araraquara, SP, Brazil
Fusidic acid is an antibiotic steroid indicated for the treatment of infections caused by the genus 
Staphylococcus, including methicillin resistant Staphylococcus aureus strains, and other Gram-positive 
bacteria. In the present study, a stability-indicating reversed-phase liquid chromatography (RP-LC) 
method was developed and validated for the determination of fusidic acid in dermatological cream as an 
alternative to existing methods. Analyses were performed using a C18 column and guard column at room 
temperature, eluting with an isocratic mobile phase of acetonitrile and water (72:28, v/v), adjusted to pH 
3.5 with acetic acid, pumped at a flow rate of 1.0 mL min-1, detection at 210 nm and 20 µL of injection 
volume. The forced degradation study was conducted under acidic, alkaline, neutral, photolytic, and 
oxidative stress conditions. The method was validated according to ICH and FDA guidelines; it was 
linear, precise, accurate, selective, and robust over concentrations of 5–95 µg mL–1, with detection and 
quantification limits of 0.43 and 1.31 μg mL–1, respectively. Therefore, we conclude that this method 
is suitable for quantifying fusidic acid in pharmaceutical dermatological creams and determining its 
stability, representing a more economical and practical alternative for routine analysis in quality control.
Uniterms: Fusidic acid/stability-indicating/quality control/validation. Chromatography/reversed-phase.
INTRODUCTION
Fusidic acid (FA), an antibiotic steroid (Godtfredsen, 
Vangedal, 1962) (Figure 1), has been used widely in 
the topical and systemic treatment of infections caused 
by Gram-positive microorganisms since 1962 (Jones 
et al, 2011; Spelman, 1999). These include strains 
resistant to penicillin and other antibiotics (França, 
2010), providing an alternative for the treatment of 
diseases caused by methicillin resistant Staphylococcus 
aureus strains, abbreviated as MRSA (Anderson, 1980; 
Falagas, Kopterides, 2007). Topical FA is prescribed by 
dermatologists for the treatment of boils, carbuncles, 
erythema, cellulitis, folliculitis, acne, paronychia, 
hidradenitis, infections resulting from burns and impetigo 
(George, Rubin, 2003; França, 2010; Smeenk, Sebens, 
Houwing, 1999; Spelman, 1999; Wilkinson, 1998), atopic 
dermatitis, neurodermatitis, prurigo, and contact dermatitis 
(Long, 2008).
Considering its importance in medical practice, 
the development of optimized analytical methods for 
the quality control of FA is essential for analyzing its 
quality, therapeutic efficacy, safety, and benefits for 
the pharmaceutical industry. Reversed phase liquid 
chromatography (RP-LC) is the technique of choice and 
FIGURE 1 - Chemical structure of fusidic acid (CAS 6990-06-3).
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occupies a prominent place among modern methods 
of analysis, due to its ease in effecting the separation, 
identification, and quantification of chemical substances 
and their degradation products (Snyder, Kirkland, Dolan, 
2010).
In the literature there are some articles that describe 
this method for the quantification of FA in biological fluids 
(Hikal, 1983; Nawaz et al., 2014; Rahman, Hoffman, 
1988; Sewell, Palmer, 1991; Sorense, 1988) and in 
pharmaceutical products (Ankam et al., 2010; British 
Pharmacopeia, 2010; Byrne, Velasco-Torrijos, Reinhardt, 
2014, 2015; Goswami, Gupta, Jogia, 2013; Hikal, Shibl, 
El-Hoofy, 1982; Hong, Rong, 2012; Peh, Tan, 2000; 
Nawaz et al., 2014; Nianfen, Yandong, Mooling, 2009; 
Shaikh et al., 2009). However, some of these methods 
are time consuming, have complex mobile phases, or 
require buffer solution, while others require long running 
times, high injection volumes and flow rates, or high FA 
concentrations in the sample.
Chromatographic methods prioritizing shorter 
analyses that are economically viable, reduce the 
quantities of waste to the environment, and are safer 
for the analyst, are of great importance and have gained 
prominence (Bonfilio et al., 2009; Lopes, Salgado, 2009; 
Moreno, Salgado, 2008; Pedroso, Salgado, 2014; Rugani, 
Salgado, 2014; Silva, Salgado, 2012; Tótoli, Salgado, 
2014; Vieira, Salgado, 2011).
Research improving the quality control of 
pharmaceutical products through analytical methods, 
besides benefiting the pharmaceutical industry, ensures 
higher product quality and increased consumer safety. 
In this sense, the aim of this study was to develop and 
validate a simple, rapid, sensitive, economic, and stability 
indicating method to quantify FA in pharmaceutical forms 
of dermatological cream, as a better alternative to existing 
literature methods.
MATERIALS AND METHODS
Chemical and reagents
HPLC grade acetonitrile, methanol, ethanol, and 
acetic acid (J. T. Baker, USA), along with deionized 
Milli-Q water (Millipore, Bedford, USA) were used to 
prepare the mobile phase. Sample VerutexTM, containing 
20 mg g–1 of the active ingredient, was supplied by LEO 
Pharma Laboratory (Itapevi-SP, Brazil). Fusidic acid 
reference standard (FA-RS), declared to be 100% pure, was 
purchased commercially from Sigma-Aldrich (Brazil). All 
adjuvants used in production of the formulation without 
the active ingredient (placebo) were of analytical grade: 
hydrochloric acid (LabSynth), cetyl alcohol (Audaz), 
butylated hydroxyanisole (Sigma-Aldrich, Brazil), 
glycerol (Ely Martins), white petrolatum (Tec-Lab), liquid 
petrolatum (Columbia), polysorbate 60 (LabSynth), and 
potassium sorbate (Rica Nata).
Instrumentation and analytical conditions
Chromatographic separations were carried out using 
a WatersTM HPLC system, equipped with a Waters 1525 
binary gradient chromatography pump, Rheodyne Breeze 
7725i manual injector, with a 20 μL loop, Waters 2487 UV-
Vis detector, and EmpowerTM software. The peak purity was 
determined using a ShimadzuTM HPLC system equipped 
with two LC-10AD pumps, SIL-10AF automatic injector, 
DAD detector SPD-M10A-VP, communication CBM-20a 
module, and LC Solution software. A digital pH meter, 
model B474 (MicronalTM), ultrasonic bath (UniqueTM), 
analytical balance model DV215CD - Class I (OHAUSTM), 
vacuum filtration system (MilliporeTM, Bedford, USA), 
nylon membranes (0.45 μm pore size, SartoriusTM), 
membrane filters (0.45 μm pore size and 13 mm diameter, 
MinisartTM - RC/SRP/NY, Sartorius Stedim Biotech), and 
filter paper (QualyTM, J. Prolab) were also used.
Chromatographic analysis was performed using an 
AgilentTM Zorbax Eclipse XDB C18 column (250 × 4.6 mm, 
5 µm) combined with a pre-column HPLC Metaguard 4.6 
mm Polaris C18 PTC 5U AgilentTM at room temperature (25 
°C). The mobile phase was composed of acetonitrile and 
water (72:28, v/v) adjusted to pH 3.5 with acetic acid. The 
flow rate was 1.0 mL min–1, the detection wavelength was 
210 nm, and the injection volume was 20 µL.
Preparation of the solutions
Preparation of standard solutions
The stock standard solution was prepared at a 
concentration of 100 μg mL–1 and used to prepare working 
solutions by diluting to the appropriate concentration 
levels using the mobile phase as diluent. These solutions 
were filtered through 13 mm membranes with pore size 
of 0.45 μm after preparation.
Preparation of sample solutions
To an amount of the cream, equivalent to a 
concentration of 100 μg mL-1 weighed into a beaker, 
was added acetonitrile and placed into ultrasound for 10 
minutes. Afterwards, the resultant solution was transferred 
to a volumetric flask, diluted to the necessary volume with 
acetonitrile, and then filtered through filter paper. Working 
solutions were prepared by diluting aliquots of the stock 
Stability-indicating RP-LC method for quantification of fusidic acid in cream 449
solution to the appropriate concentration, using the mobile 
phase as the diluent. These solutions were filtered through 
13 mm membranes with pore size of 0.45 μm.
Preparation of placebo solutions
The stock placebo solution was prepared in the 
same manner as the sample, but without FA. Working 
solutions were prepared by diluting aliquots of the stock 
solution to the appropriate concentration, using the mobile 
phase as the diluent. These solutions were filtered through 
membrane filters after preparation.
Development and optimization of the 
chromatographic method
Various chromatographic parameters were evaluated 
during the development and optimization of the RP-LC 
method, as shown in Table I.
System suitability testing
System suitability test was performed by injecting 
seven replicates of the FA-RS solution at a concentration 
of 50 µg mL–1. The number of plates, retention factor 
(k’), and asymmetry were evaluated according to 
FDA specifications (1994). In addition, the relative 
standard deviation (RSD) of the retention time and the 
chromatographic peak areas of FA were also analyzed.
Method validation
Method validation was performed following FDA 
(1994) and ICH (2005) specifications for linearity, 
precision, accuracy, selectivity, robustness, and detection 
and quantitation limits.
Linearity
The linearity was analyzed in triplicate, based on the 
results obtained from the analytical curve. The analytical 
curve was generated by plotting the peak area at each 
concentration level (n=3) versus drug concentrations of 5, 
20, 35, 50, 65, 80, and 95 µg mL–1. Statistical evaluation 
was performed by linear least squares regression mean 
(ANOVA) at a significance level of 5%, wherein the 
analysis of residues was also conducted.
Precision
Precision was assessed by repeatability (intra-
assay) and intermediate precision (inter-assay). The 
precision by repeatability was verified by analysis of 
nine determinations covering the linear range of the 
method, i.e., three concentrations: low concentration 
(5 µg mL–1), medium (50 μg mL–1) and high (95 µg mL–1) 
obtained from the calibration curve. This procedure was 
performed in triplicate on the same day, under the same 
experimental conditions, in the same laboratory, and 
by the same analyst. Intermediate precision was also 
checked by the analysis of nine determinations covering 
the linear range of the method. However, this procedure 
was performed by different analysts on different days. 
In both analyses, the results were evaluated based on 
the RSD.
Accuracy
Accuracy was determined by recovery tests, also 
called recovery factors (ICH, 2005), in which known 
quantities of FA-RS were added to known amounts of the 
sample. This parameter was analyzed in triplicate at three 
levels of recovery from the median of the concentration 
curve (50 µg mL–1, R2 = 100%), wherein, R1 consisted 
of 80% (40 µg mL–1) and R3 of 120% (60 µg mL–1), as 
TABLE I - Chromatographic parameters tested for development in the RP-LC method
Parameters Description
Mobile phase Ethanol and water (different ratios and pH)  
Methanol and water (different ratios and pH)  
Acetonitrile and water (different ratios and pH)
Column Zorbax Eclipse XDB C18 – AgilentTM (4.6 x 250 mm, 5 µm)
Guard column Metaguard Polaris 4.6 mm 5U C18 PTC – AgilentTM
Wavelength Determined by scanning by spectrophotometry absorption in the UV region
Flow rate 0.5 mL min–1; 1.0 mL min–1; 1.3 mL min–1
Injection volume 20 µL
Elution mode Isocratic
Temperature 25±1 °C
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established by the FDA (1994). The recovery percentage 
of the drug was calculated using Equation 1, determined 
by the Association of Official Analytical Chemists (2002).
  Equation 1
where Cf is the total drug concentration measured after 
standard addition; Cu is the total drug concentration in the 
formulation; Ca is the standard concentration added to the 
formulation.
Selectivity and studies of forced degradation
The selectivity of the method was evaluated by 
observing the chromatograms of FA-RS, free analyte in 
the matrix (placebo), array added analyte (sample) at the 
working concentration of 50 μg mL–1, and the mobile 
phase (acetonitrile and water, 72:28, v/v, pH 3.5). The 
purity of the chromatographic peak of FA was analyzed 
using a diode array detector (DAD).
In order to assess the selectivity of the method 
in relation to degradation products and prove that the 
method was stability indicating, a forced degradation 
study was performed using FA solution at a concentration 
of 50 μg mL–1. This study was conducted under acidic 
(0.01 mol L–1 HCl neutralized with 0.01 mol L–1 
NaOH), alkaline (0.001 mol L–1 NaOH neutralized with 
0.001 mol L–1 HCl), neutral (ultrapure water), oxidative 
(3% H2O2), and photolytic (UV 254 nm, 20 W) stress 
conditions. The first four reactions were carried out at 
60 °C, while photolytic stress, in which the solution was 
exposed to UV light, was conducted at room temperature. 
Degradation was stopped when approximately 5-20% 
of the FA had degraded (Alsante et al., 2007). The 
degradation conditions promoted the appearance of 
other chromatographic peaks and their resolution was 
assessed.
Robustness
The robustness of the method was evaluated by 
Youden test through a dosage performed assay using a 
concentration of 50 μg mL–1. The Youden test evaluates 
seven variables, combined in eight experiments, in which 
the nominal conditions (normal) are represented by 
uppercase letters and the changed conditions, lower case. 
The variables must be consistent with practical reality 
and levels should reflect generally observed variation 
(Youden, Steiner, 1975). For this reason, changes were 
evaluated both with “upper” and “lower” chromatographic 
parameters (Table II). The results were obtained through 
averaging the subtraction of the values of normal 
conditions from the values of changed conditions. For 
the method to be considered robust, the differences in the 
values should be smaller than twice the SD of all means 
in the test (Youden, Steiner, 1975).
Detection limit (LD) and quantitation limit (LQ)
The LD and LQ of the method were obtained from 
Equations 2 and 3, respectively:
 LD = 3 (SD/a) Equation 2
 LQ = 10 (SD/a) Equation 3
where SD is the standard deviation of the intersection and 
a is the mean slope, obtained from calibration curves of 
the linearity study.
RESULTS AND DISCUSSION
Development and optimization of the 
chromatographic method
In this study we used octadecylsilane (C18) as 
the stationary phase because of its easy accessibility in 
laboratories and ability to separate solutes of different 
polarities, molecular weights, and chemical features. As 
the sample analyzed was composed of a complex matrix, 
a guard column was used to remove particles that would 
TABLE II - Chromatographic parameters and their changes 
“lower” and “upper” used to assess the robustness of the RP-
LC method
Variables Changes “lower” and “upper”
Lot Column AgilentTM 
(250 x 4.6 mm, 5 μm)
A: B08125 
a: B09180
pH B: 3.5 b: 3.4 and 3.6
Flow rate (mL min–1) C: 1.0 c: 0.9 and 1.1
Acetonitrile brand D: J. T. Baker d: Tedia
Proportion of mobile phase 
 (acetonitrile/water)
E: 72:28 
e: 70:30 and 74:26
Wavelength (nm) F: 210 f: 209 and 211
Temperature (°C) G: 25 g: 23 and 27
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have strong interactions with the stationary phase (Snyder, 
Kirkland, Dolan, 2010). This promoted an increased 
lifetime for the chromatographic column.
Regarding the analyzed mobile phases, that 
consisting of acetonitrile and water (72:28, v/v) adjusted to 
pH 3.5 with acid acetic acid exhibited better performance, 
better peak definition, higher efficiency, higher sensitivity, 
and shorter analysis time. In addition, acetonitrile is 
a lower viscosity solvent than ethanol and methanol, 
which allows the pressure in the analysis to be very low, 
considerably increasing the lifetime of the column and 
the chromatographic system. Determination of the mobile 
phase pH was a parameter that required caution because 
a very acidic pH could compromise the integrity of the 
chromatographic system (Snyder, Kirkland, Dolan, 2010). 
Furthermore, potential ionization of the analyte should be 
considered when choosing pH, so that no chromatographic 
peak has a low efficiency and/or peak tails. Accordingly, 
in mobile phases of pH ≥ 4.0, we observed a considerable 
decrease in chromatographic efficiency.
For the flow rate, it was observed that to obtain a 
satisfactory retention factor, defined by the FDA (1994) 
as ≥ 2, the flow rate should be below 1.3 mL min–1. On 
the other hand, a flow rate of 0.5 mL min–1 promoted peak 
broadening, which consequently reduced chromatographic 
efficiency. The broadening of a chromatographic peak is 
a result of the processes of diffusion and mass transfer. 
The diffusion may either be turbulent (Eddy diffusion) or 
longitudinal (Snyder, Kirkland, Dolan, 2010).
Therefore, the method developed, besides being 
indicative of stability, had a retention time (Ankam et al., 
2010; Byrne, Velasco-Torrijos, Reinhardt, 2014; Goswami, 
Gupta, Jogia, 2013), flow rate (Ankam et al., 2010; British 
Pharmacopeia, 2010; European Pharmacopeia, 2010), and 
injection volume (Ankam et al., 2010) lower than other 
methods described in the literature for the quantification 
of FA in dermatological cream. This results in a reduced 
consumption of organic solvents, thus lowering both the 
cost of the method and the amount of toxic waste generated 
to the environment.
This method also has advantages in mobile phase 
composition when compared with other methods (Ankam 
et al., 2010; Hong, Rong, 2012; Shaikh et al., 2009), 
because, as well as being simple, the use of buffer was 
avoided. Using buffer solutions is disadvantageous for 
the pharmaceutical industry because they are expensive, 
require preparation prior to analysis because storage 
can cause fungus growth even when refrigerated, and 
are generally responsible for increased pressure in the 
chromatographic system by causing clogging that impairs 
the functionality of the equipment and damages the 
columns, thus decreasing their useful lifetime (Snyder, 
Kirkland, Dolan, 2010; Watson, 2005).
System suitability testing
Tests that assess conformity of the system (system 
suitability) should be performed before the validation 
procedure or even before routine analysis. The compliance 
test is defined as a set of experiments designed to ensure 
that the equipment and the method that is being developed 
is able to generate results with satisfactory accuracy and 
precision (Paschoal et al., 2008).
According to the FDA (1994), for the system to be 
considered reliable and reproducible, it is necessary to 
perform at least two of the following tests: repeatability, 
resolution, asymmetry, number of plates, and retention 
factor. Asymmetry is a very important parameter because 
it prevents broadening of the chromatographic peak, 
which can, in turn, produce errors in measuring analytes 
of interest (Snyder, Kirkland, Dolan, 2010).
The number of plates can be affected by several 
factors, including analysis conditions, amount of sample 
or solute, and, in particular, column length. The retention 
factor is intended to ensure that the proposed method is 
able to produce a suitable chromatographic separation. 
This parameter is closely related to the retention time 
of the analyte. A low retention factor, provided that it is 
within acceptable limits, promotes lower costs, a shorter 
analysis, and, consequently, decreased waste production 
(Snyder, Kirkland, Dolan, 2010).
System suitability testing showed that the chromato-
graphic parameters in the development of this method 
were able to provide accurate and reliable results, since 
the average value calculated for asymmetry was less than 
2.0, and the average plate number and retention factor 
were greater than 2000 and 2.0, respectively, as specified 
by the FDA (1994). Furthermore, adequate precision was 
observed for the values of retention time (about 8 minutes) 
and chromatographic peak areas of FA, which had an RSD 
below 2%, which is recommended for conformance testing 
(FDA, 1994).
Method validation
Linearity
The linearity parameter was confirmed in the 
concentration range 5–95 µg mL–1, wherein the calibration 
equation and correlation coefficient (r) were y = 19080x 
+ 7004.5 and 0.9999, respectively. In the statistical 
analysis, results showed that the method had satisfactory 
linear regression because the p-value was 4.97604x10-11. 
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In addition, in the analysis of the waste (Figure 2), the 
points randomly distributed, which is also indicative of 
good regression.
Precision
In analyzing the method by repeatability and 
intermediate precision (Tables III and IV, respectively), 
the RSDs of areas obtained in all concentrations analyzed 
were no more than 2%, indicating good precision of the 
chromatographic method.
Accuracy
The recovery test showed that the method had 
satisfactory accuracy to measure FA in dermatological 
cream, since the percentage value of the average recovery 
was close to 100%, as shown in Table V.
Selectivity and studies of forced degradation
Analysis of the selectivity parameter (Figure 3) 
demonstrated that the adjuvants and mobile phase do not 
cause any interference in the peak of FA. The purity of 
the chromatographic peak of FA was calculated as 100% 
using a DAD.
FIGURE 2 - Residue analysis for fusidic acid obtained by the 
RP-LC method.
TABLE III - Precision by repeatability for fusidic acid by RP-LC method
Concentration (μg mL–1) Area Mean area ± SD* RSD† (%)
5
108930 
108752 
106989
108223.67 ± 1072.95 0.99
50
977933 
985407 
969249
977529.67 ± 8086.55 0.83
95
1861386 
1885479 
1893760
1880208.33 ± 16818.26 0.89
*SD = standard deviation; †RSD = relative standard deviation.
TABLE IV - Intermediate precision for fusidic acid by RP-LC method
Concentration 
(μg mL–1)
ANALYST1 ANALYST2
Area Mean area ± SD* RSD† (%) Area Mean area ± SD* RSD† (%)
5
108930 
108752 
106989
108223.67 ± 
1072.95 0.99
108812 
105983 
106281
107025.33 ± 
1554.46 1.45
50
977933 
985407 
969249
977529.67 ± 
8086.55 0.83
975625 
990514 
984641
983593.33 ± 
7499.59 0.76
95
1861386 
1885479 
1893760
1880208.33 ± 
16818.26 0.89
1889630 
1872788 
1854167
1872195.00 ± 
17738.94 0.95
*SD = standard deviation; †RSD = relative standard deviation.
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Table VI shows the results obtained under 
degradation conditions, namely acidic, alkaline, neutral, 
photolytic, and oxidative stress. Additional degradation 
peaks were observed under neutral, acidic, and photolytic 
conditions (Figure 4), in which the chromatographic 
resolutions were satisfactory (2.49, 11.36, and 12.70, 
respectively). Resolution is a measure of the separation 
between two adjacent peaks and must produce values of ≥ 
2.0, to be judged as adequate (FDA, 1994). Under all the 
stress conditions there was a decrease in the peak area of 
FA. The drug was most stable under photolytic condition, 
while maximum degradation was observed under alkaline 
condition. All of these results combined to demonstrate 
that the method, as well as being selective, is indicative 
of stability, because it was able to differentiate FA from 
the other degradation products observed.
Robustness
In the analysis of robustness using the Youden Test, 
no significant effect was observed in the method when 
subjected to the proposed changes, because all “lower” 
changes had effects lower than 1.94 and all “upper” 
changes had effects lower than 1.10 (Table VII). These 
values corresponded with the values of twice the SD of 
all the means of the respective assays (0.97 and 0.55, 
respectively).
This test not only assessed whether the method is 
TABLE V - Accuracy for fusidic acid by RP-LC method
FA-RS added 
(μg mL–1)
FA-RS found* 
(μg mL–1)
Recovery 
(%)
Mean recovery 
(%) SD
†
R1 40 40.68 100.63 101.22 0.52
R2 50 50.88 101.38
R3 60 61.16 101.64
*Mean of three determinations; †SD = standard deviation.
FIGURE 3 - Chromatogram showing the selectivity of the RP-LC method in the quantification of fusidic acid.
TABLE VI - Forced degradation study of fusidic acid
Stress condition Time Degradation (%)
Acid hydrolysis  
(0.01 mol L–1 HCl)
0 h
1 h
5 h
9 h
24 h
3.23
4.32
7.78
14.48
30.10
Alkaline hydrolysis  
(0.001 mol L–1 NaOH)
0 h
1 h
17.97
35.20
Neutral (ultrapure water)
0 h
1 h
5 h
9 h
24 h
48 h
72 h
0.50
0.75
1.00
3.78
7.38
14.26
27.70
Photolytic (UV 254 nm)
0 h
1 h
5 h
9 h
24 h
48 h
6 days
10 days
0.35
0.63
1.08
4.36
3.92
6.25
6.33
13.93
Oxidation (3% H2O2)
0 h
1 h
5 h
5.01
14.33
95.84
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robust, but also indicates the influence of each parameter 
on the analytical results. The premise of the test is to 
introduce many changes at once in order to determine the 
effect of individual changes (Youden, Steiner, 1975). In 
this instance, the effects obtained from variation of the 
different parameters were not significant and therefore the 
method was considered robust.
Detection limit (LD) and quantitation limit (LQ)
The values calculated for the LD and LQ were 0.43 
μg mL–1 and 1.31 μg mL–1, respectively. These values 
indicated the ability of the method to reliably detect 
and quantify FA dermatological cream formulations 
established in the linear range.
CONCLUSION
The proposed RP-LC method for the quantification 
of FA in the form of pharmaceutical dermatological 
cream is fast, simple, efficient, economical, and sensitive 
compared to other methods described in the literature, and 
is stability indicating. All parameters were in accordance 
with the acceptance criteria for the validation of methods 
established by the ICH and FDA. Therefore, the validated 
method could easily be applied to the routine analysis of 
FA in the pharmaceutical industry.
FIGURE 4 - Chromatograms obtained in the forced degradation study of fusidic acid. Degradation conditions: A: Acid hydrolysis 
(0.01 mol L–1 HCl), B: Alkaline hydrolysis (0.001 mol L–1 NaOH), C: Neutral (ultrapure water), D: Photolytic (UV 254 nm), and 
E: Oxidative stress (3% H2O2).
TABLE VII - Effects observed in the robustness evaluation of 
the RP-LC method
Variable
| Effects |
Changes 
“lower”
Changes 
“upper”
Lot Column AgilentTM  
(250 x 4.6 mm, 5 μm)
0.37 –0.20
pH –0.51 0.68
Flow rate (mL min-1) 0.32 0.29
Acetonitrile brand 0.58 0.33
Proportion of mobile phase 
(acetonitrile and water)
–1.35 –0.45
Wavelength (nm) 0.22 –0.39
Temperature (ºC) –0.77 –0.05
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